Document:

EX-10.10

 Exhibit 10.10 

ROKA BIOSCIENCE, INC. 

EMPLOYEE CONFIDENTIALITY, INVENTIONS, 

NON-INTERFERENCE, NON-SOLICITATION AND NON-COMPETITION AGREEMENT 

This Agreement is entered into as of
                             by and between Roka Bioscience, Inc., a Delaware corporation (the
“Company”), and the person identified on the signature page to this Agreement (the “Employee”). 
 In
consideration of, and as part of the terms of, the employment or continued employment of the Employee by the Company, the compensation paid and to be paid by the Company to the Employee, the entrusting to the Employee of certain of the
Company’s trade secrets and proprietary information, and the mutual covenants and promises set forth herein, the Employee and the Company agree as follows: 

1. Confidentiality. 
 (a) The Employee
recognizes and acknowledges that the Company’s Confidential Information (as hereinafter defined) is a valuable, special and unique asset of the Company’s business, access to and knowledge of which are essential to the performance of the
Employee’s duties as an employee of the Company. The Employee further acknowledges that it is vital to the Company’s legitimate business interests that the confidentiality of such Confidential Information be preserved, and that use or
reliance on such Confidential Information by or on behalf of any other business or commercial activity in competition with the Company could result in irreparable harm to the Company. The Employee further acknowledges that the Confidential
Information is and shall remain the exclusive property of the Company and nothing in this Agreement shall be construed as a grant to the Employee of any rights, title or interest in, to or under the Confidential Information. Without limitation of
the Company’s rights and remedies under this Agreement and at law or in equity arising out of the Employee’s unauthorized use or disclosure of the Company’s Confidential Information during or after his/her employment, the Employee
understands that his/her unauthorized use or disclosure of Company Confidential Information during his/her employment will lead to disciplinary action, up to and including immediate termination of employment. 

(b) The Employee shall not, during Employee’s employment by the Company or at any time following the termination of Employee’s employment by
the Company (regardless of whether termination was initiated by the Company or the Employee and for any reason or no reason), in whole or in part: (i) disclose such Company Confidential Information to any person, firm, corporation, association
or other entity for any reason or purpose whatsoever; or (ii) make use of any such Confidential Information for the Employee’s own purposes, for the benefit of any person, firm, corporation or other entity (except the Company), or in any
manner adverse to the interests of the Company under any circumstances; provided that the restrictions in this Section 1(b) shall not apply to such Company Confidential Information which the Employee can establish by clear and convincing
written proof: 
  

	 	(i)	at the time of disclosure by the Employee, was generally known or available to persons engaged in the trade of the Company through no act or omission of the Employee; 

 

	 	(ii)	was known to the Employee prior to its disclosure to the Employee by the Company, its officers or directors, its other employees, its suppliers or customers, its agents or consultants during the Employee’s
employment by the Company; 

  

	 	(iii)	is disclosed to the Employee at any time other than in the course of the Employee’s performance of his/her duties as an employee of the Company, by any third party not bound at the time of the disclosure, directly
or indirectly, by any confidentiality agreement with the Company; or 

  
 1 

	 	(iv)	is disclosed by the Employee in response to a request or order of any court or governmental agency; provided that the Employee shall have promptly notified the Company prior to any disclosure under this clause
(iv) and provided reasonable cooperation in the Company’s efforts, if any, to contest or limit the scope of such disclosure and provided further that if such disclosure under this clause (iv) is the subject of any protective or
similar order, such information will still be considered Confidential Information except for the limited purpose of disclosure to such court. 

(c) The Employee will safeguard the Confidential Information by all reasonable steps and abide by all policies and procedures of the Company in place from time
to time regarding storage, copying, destroying, publication or posting, or handling of such Confidential Information, in whatever medium or format that Confidential Information takes. 

(d) All originals, copies, digests and summaries of all written or otherwise recorded documents, writings, materials, software or other media, or items
or information of any kind, concerning any matters affecting or relating, directly or indirectly, to the Company’s business, products or services, whether or not they contain or embody Company Confidential Information or any Inventions (as
hereinafter defined), are and shall continue to be the exclusive property of the Company. Immediately upon any termination of the Employee’s employment or at any time upon the request of the Company, the Employee shall deliver to the Company
(and not retain any copies or reproductions) all of such documents, writings, materials, software or other media, or items and information, together with all other property belonging to the Company, then in the Employee’s actual or potential
possession, custody or control. If the material is such that it cannot reasonably be delivered, the Employee shall provide reasonable evidence that such materials have been destroyed, including but not limited to, the purging and/or erasing of any
and all computer records and/or data files. 
 (e) The term “Company Confidential Information” means any and all Inventions and
all information which is acquired by the Employee from the Company, its officers or directors, its other employees, its suppliers or customers, its agents or consultants during the Employee’s employment by the Company, and which relates to the
present or potential businesses, products or services of the Company, or to the Company’s technical data, trade secrets, know-how or Inventions and all tangible materials which embody such information (e.g., compounds, genes, proteins,
cell lines, formulations, samples, devices, or other compositions of matter), as well as any structural information and/or any methods of synthesis relating to such tangible materials; provided, that Company Confidential Information does not include
any of the foregoing items to the extent the same have become publicly known and made generally available through no wrongful act of Employee or of others. 

(f) The Employee acknowledges that the Company may have received and in the future may receive confidential or proprietary information from third parties
associated with the Company, including the Company’s customers, suppliers, licensors, licensees, partners, or collaborators (“Third Party Confidential Information”). The Employee covenants and agrees that s/he shall at all
times during his/her employment with the Company and thereafter, (i) hold such Third Party Confidential Information in the strictest confidence, (ii) not use or disclose to any person, firm or corporation any such Third Party Confidential
Information, except as necessary in carrying out his/her work for the Company consistent with the Company’s agreement with the applicable third party, and (iii) safeguard such Third Party Confidential Information by all reasonable steps
and abide by all policies and procedures of the Company and such third parties in effect from time to time regarding storage, copying, destroying, publication or posting, or handling of such Third Party Confidential Information, in whatever medium
or format that Third Party Confidential Information takes. Without limitation of the Company’s rights and remedies under this Agreement and at law or in equity arising out of the Employee’s unauthorized use or disclosure of Third Party
Confidential Information during or after his/her employment, the Employee understands that his/her unauthorized use or disclosure of any Third Party Confidential Information during his/her employment will lead to disciplinary action, up to and
including immediate termination of employment. 

  
 2 

 (g) The Employee covenants and agrees that he/she will execute and abide by any and all other confidentiality
agreements that the Company reasonably requests the Employee to sign or abide by, whether those agreements are for the benefit of the Company or any third parties associated with the Company (including, without limitation, the Company’s
customers, suppliers, licensors, licensees, partners, or collaborators). 
 (h) The Employee represents and warrants that he/she does not have any
non-disclosure, non-compete, non-solicitation or other obligation to any previous or concurrent employer or any other person or entity that would prohibit, limit, conflict or interfere with the Employee’s obligations under this Agreement or the
performance of his/her duties for the Company. The Employee covenants that during his/her employment with the Company, the Employee will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any
former or concurrent employer or other person or entity. The Employee furthers covenants that s/he will not bring onto the premises of the Company or transfer onto the Company’s technology systems any unpublished document, proprietary
information or trade secrets belonging to any such employer, person or entity unless consented to in writing by both Company and such employer, person or entity. 

2. Intellectual Property and Inventions.

(a) The Employee hereby assigns and agrees to assign to the Company, or its’ designee, the entire right, title and interest of the Employee in and to
all inventions, ideas, discoveries, improvements, Confidential Information, know-how, innovations, writings, works and other developments or improvements (whether or not protectable under patent, copyright, trade secret or similar laws) made,
discovered, invented, authored, created, developed, originated or conceived by the Employee, solely or jointly, during the course of the Employee’s employment by the Company, which: (i) arise out of research or any other activities
conducted by, for or under the direction of the Company, (whether or not such activities are conducted at the Company’s facilities, during working hours or using Company assets or Company Confidential Information) except as provided in
Section 2(d), or (ii) relate directly or indirectly to methods, programs, computer software, apparatus, designs, plans, models, specifications, formulations, techniques, products, processes or devices, sold, leased, used or under
consideration or development by the Company (together with all intellectual property rights, worldwide, with respect to any of the foregoing, hereinafter collectively “Inventions”). The Employee acknowledges that all copyrightable
materials developed or produced by the Employee within the scope of the Employee’s employment by the Company constitute works made for hire, as that term is used in the U.S. Copyright Act. To the extent that any Invention is found not to be a
“work made for hire” as a matter of law, the Employee hereby irrevocably assigns to the Company all of his/her right, title and interest in and to that Invention. Upon the Company’s request, at any time during or after the
Employee’s employment by the Company, the Employee shall sign all written documents of assignment that the Company believes are necessary to formally evidence the Employee’s irrevocable assignment to the Company of any such Invention. The
Employee understands and agrees that the decision whether or not to commercialize or market any Invention is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty or other consideration will be due to
the Employee as a result of the Company’s efforts to commercialize or market any such Inventions. The Employee warrants and represents that the Inventions will not knowingly infringe any intellectual property rights of any third party. 

(b) The Employee shall keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by Employee (solely or jointly
with others) during the course of his/her employment with the Company. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that may be specified by the Company. The records are Company
Confidential Information and will be available to and remain the sole property of the Company at all times. 

  
 3 

 (c) The Employee shall communicate promptly and disclose to the Company (and to no other person or entity),
in such form as the Company may reasonably request, all information, details and data pertaining to any such Inventions, and the Employee shall assist the Company, or its designee, at the Company’s expense, in every proper way to secure the
Company’s rights in the Inventions and any rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications,
oaths, assignments and all other instruments which the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend, and enforce such rights and in order to assign and convey to the Company, its successors,
assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions and any rights relating thereto, and testifying in a suit or other proceeding relating to such Inventions and any rights relating thereto. Employee
further agrees that his/her obligation to execute or cause to be executed, when it is in his/her power to do so, any such instrument or papers shall continue after the termination of his/her employment with the Company. If the Company is unable
because of Employee’s mental or physical incapacity or for any other reason to secure Employee’s signature with respect to any Inventions including, without limitation, to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering such Inventions, then Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee’s agent and attorney-in-fact, to act for and in
Employee’s behalf and stead to execute and file any papers, oaths and to do all other lawfully permitted acts with respect to such Inventions with the same legal force and effect as if executed by Employee. 

(d) It is understood and agreed by Company and Employee that the provisions of this Section 2 requiring assignment of Inventions to the Company may
not apply to any Invention that qualified fully under Section 2870 of the California Labor Code, a copy of which is attached as Attachment 1. The Employee shall, however, comply with the provisions of Section 2(b) and
disclose any Inventions that Employee believes meet the criteria of Section 2870 (indicating whether Employee believes that such Inventions are covered by Section 2870). The Company shall hold any disclosure made pursuant to this
Section 3(d) in confidence in accordance with the provisions of this Agreement. Employee has provided on Attachment 2 a list describing all inventions, discoveries, original works of authorship, developments, improvements,
and trade secrets, which were conceived in whole or in part by Employee prior to his/her employment with the Company to which s/he have any right, title or interest, which are subject to California Labor Code Section 2870 and which relate to
the Company’s proposed business, products, or research and development (“Prior Inventions”); or, if no such list is attached, Employee represents and warrants that there are no such Prior Inventions. The items on such list, and
only those items, shall be excluded from the restrictions set forth in this Agreement. Employee represents and warrants that the inclusion of any Prior Inventions from Attachment 2 will not materially affect Employee’s ability to
perform all obligations under this Agreement. If, in the course of Employee’s employment with the Company, Employee incorporates into or uses in connection with any Invention any Prior Invention, Employee hereby grants to the Company a
nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license, with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, and sell such Prior Invention as part of or in
connection with such Invention related thereto. 
 3. Non-Interference; Non-Solicitation; Non-Competition.  

(a) During the Employee’s employment by the Company, the Employee will comply with all policies and rules that may from time to time be established
by the Company, and will not engage directly or indirectly in any business or enterprise which in any way is competitive or conflicting with the interests or business of the Company. 

(b) If the Employee’s employment with the Company is terminated for any reason whatsoever, regardless of whether such termination was initiated by
the Company or the Employee and regardless of the reason or absence of reason, then continuing for a period of one (1) year after such termination (such period not to include any period(s) of violation of this Section 3(b) or period(s) of
time required for litigation to enforce its provisions), the Employee shall not, directly or indirectly: (i) interfere with (or assist any third party in interfering with) any of the contractual relations between the Company and any of its
employees, consultants, independent contractors 

  
 4 

 
or agents; (ii) solicit or induce (or assist any third party in soliciting or inducing) any individual or entity that is (at the time of the solicitation or inducement) an employee,
consultant, independent contractor, consultant or agent of the Company to leave the employment of the Company or cease performing services as an independent contractor, consultant or agent of the Company; or (iii) employ, hire, retain or engage
(or assist any third party in employing, hiring, retaining or engaging) any individual or entity that is or was (at any time within the twelve (12) month period ended on the date of termination of the Employee’s employment) an employee,
independent contractor, consultant or agent of the Company. 
 (c) If the Employee’s employment with the Company is terminated for any reason
whatsoever, regardless of whether such termination was initiated by the Company or the Employee and regardless of the reason or absence of reason, then continuing for a period of one (1) year after such termination (such period not to include
any period(s) of violation of this Section 3(c) or period(s) of time required for litigation to enforce its provisions), the Employee shall not, directly or indirectly contact, communicate, solicit, or transact any business with (or assist any
third party in contacting, communicating, soliciting, or transacting any business with) any individual or entity that is or was (at any time within the 12 months prior to the contact, communication, solicitation, or transaction) a customer,
supplier, distributor, licensor, licensee, partner, or collaborator of the Company (or individual or entity who or which, at any time within the 12 months prior to the contact, communication, solicitation, or transaction, the Company contacted,
communicated with or solicited for the purposes of becoming a customer, supplier, distributor, licensor, licensee, partner, or collaborator of the Company and the Employee was in any way involved or otherwise had knowledge of or reasonably should
had have had knowledge of such contact, communication, or solicitation) for the purposes of inducing such customer, supplier, distributor licensor, licensee, partner or collaborator to (i) be connected to or benefit from any business
competitive with that of the Company, or (ii) terminate or limit its or their business relationship with the Company. 
 (d) If the Employee’s
employment with the Company is terminated for any reason whatsoever, regardless of whether such termination was initiated by the Company or the Employee and regardless of the reason or absence of reason, then continuing for a period of one
(1) year after such termination (such period not to include any period(s) of violation of this Section 3(d) or period(s) of time required for litigation to enforce its provisions), the Employee shall not, anywhere in the United States or
any other country or territory in which the Company conducts business, directly or indirectly, whether alone or as an employee, employer, consultant, independent contractor, agent, principal, partner, joint venture, stockholder, member, officer,
director or otherwise of any individual, entity or other business enterprise, or in any other individual or representative capacity, (i) engage in, assist in, participate in, or otherwise be connected to or benefit from any Competitive Business
(as defined below), or (ii) take any steps or actions to facilitate or prepare to engage in, assist in, participate in, or otherwise be connected to or benefit from any Competitive Business. As used in this Section 3(d),
“Competitive Business” shall mean any individual, entity or business enterprise that (i) is engaged in or provides or is seeking to engage in the development and commercialization of molecular assays for biopharmaceutical
production, water and food safety testing and other industrial applications; or (ii) is engaged in or provides or is seeking to engage in or provide any product, service or other business which is of the same nature as a product, service or
other business of the Company or a product, service or other business which the Company was developing during the period of the Employee’s employment and of which the Employee had knowledge or reasonably should have had knowledge. Without
limitation of the foregoing, the Employee expressly agree that, during the one (1) year period following the termination of his/her employment with the Company, the Employee will not, directly or indirectly, become employed or engaged by,
transact business with, or otherwise be connected to or benefit from any of the following businesses: (a) Dupont Qualicon; Roche Molecular; Biomerieux; Life Technologies Corporation; Neogen Corporation; or Pall Corporation, as well as each of
their respective successors and assigns; and (b) any affiliate of any the foregoing businesses that are engaged in a Competitive Business. 

 (e) If at any time any of the provisions of this Section 3 shall be deemed invalid or unenforceable or
are prohibited by the laws of the state or place where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or scope of activities restricted, or for any other reason, such provisions shall be considered
divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and enforceable by the court or other body having jurisdiction over this Agreement; and the Company and
the Employee agree that the provisions of this Section 3, as so amended, shall be valid and binding as though any invalid or unenforceable provision had not been included herein. 

4. Conflicts; Company Policies. (a) The Employee shall not during the course of his/her employment with the Company, engage in or
undertake any other employment, occupation, consulting relationship or commitment that is directly related to the business in which the Company is now involved or becomes involved or has plans to become involved, nor will the Employee engage in any
other activities that conflict with his/her obligations to the Company. 
 (b) The Employee represents that s/he has no other agreements, relationships
or commitments to any other person or entity that conflict with Employee’s obligations to the Company under this Agreement or conflict with or limit his/her ability to become employed and perform the services for which Employee is being hired
by the Company. Employee further covenants that if s/he has signed a confidentiality agreement or similar type of agreement with any former employer or other entity, s/he will comply with the terms of any such agreement to the extent that its terms
are lawful under applicable law. Employee represents and warrants that after undertaking a careful search (including searches of his/her computers, cell phones, electronic devices and documents), s/he has returned all property and confidential
information belonging to all prior employers. 
 (c) Employee will diligently adhere to all policies of the Company including the written
insider’s trading policies and conflict of interest policies adopted by the Company from time to time during Employee’s employment. 

(d) Employee acknowledges that s/he has no reasonable expectation of privacy in any computer, technology system, email, handheld device, telephone, or
documents that are used to conduct the business of the Company. As such, the Company has the right to audit and search all such items and systems, without further notice to Employee, to ensure that the Company is licensed to use the software on the
Company’s devices in compliance with the Company’s software licensing policies, to ensure compliance with the Company’s policies, and for any other business-related purposes in the Company’s sole discretion. Employee understands
that s/he is not permitted to add any unlicensed, unauthorized or non-compliant applications to the Company’s technology systems and that s/he shall refrain from copying unlicensed software onto the Company’s technology systems or using
non-licensed software or web sites. Employee understands that it is his/her responsibility to comply with the Company’s policies governing use of the Company’s documents and the internet, email, telephone and technology systems to which
Employee will have access in connection with his/her employment. 
 (e) Upon separation from employment with the Company or on demand by the Company
during his/her employment, Employee will promptly deliver to the Company, and will not retain, recreate or deliver to anyone else, any and all Company property, including, but not limited to, Company Confidential Information, Third Party
Confidential Information, as well as all devices and equipment belonging to the Company (including computers, handheld electronic devices, telephone equipment, and other electronic devices), Company credit cards, records, data, notes, notebooks,
reports, files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, photographs, charts, all documents and property, and reproductions of any of the aforementioned items that were developed by Employee
pursuant to his/her employment with the Company, or obtained by Employee in connection with his/her employment with the Company, or otherwise belonging to the Company, its successors or assigns, including, without limitation, those records
maintained pursuant to Section 2(b). Employee also consents to an exit interview to confirm his/her compliance with this Section 4 and consents to notification by the Company to his/her new employer about Employee’s obligations under
this Agreement. 

  
 6 

 5. Enforcement; Arbitration.

(a) Employee acknowledges that the restrictions on the activities in which he/she may engage that are set forth in this Agreement and the location and
period of time for which such restrictions apply are reasonable and necessary to protect the legitimate business interests of the Company and shall survive the termination of the Employee’s employment. The Employee further acknowledges that the
restrictions contained in this Agreement will not prevent the Employee from earning a livelihood during the applicable period of restriction. 
 (b) It is
the intention of the parties to this Agreement that the covenants and restrictions in this Agreement be given the broadest interpretation permitted by law. In the event that any court of competent jurisdiction or arbitrator shall determine that one
or more of the provisions contained in this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited and restricted to the extent that the court or arbitrator shall deem such provision to be enforceable 

(c) The Employee acknowledges and agrees that the Company will suffer irreparable injury and damage and cannot be reasonably or adequately compensated in
monetary damages for the loss by the Company of its benefits or rights under this Agreement as the result of a breach, default or violation by the Employee of the Employee’s obligations under Sections 1, 2, 3 or 4 of this Agreement.
Accordingly, the Company shall be entitled, in addition to all other remedies which may be available to it (including monetary damages), to injunctive and other available equitable relief, without bond, in any court of competent jurisdiction to
prevent or otherwise restrain or terminate any actual or threatened breach, default or violation by the Employee of any provision contained in Sections 1, 2, 3 or 4 of this Agreement or to enforce any such provision. 

(d) Each of the Company and the Employee hereby acknowledge that any and all controversies, claims, or disputes arising out of, relating to, or resulting
from this Agreement, shall be subject to binding arbitration in accordance with the provisions of the offer letter between the Company and the Employee; provided that neither party shall be prohibited from seeking injunctive or other
equitable relief in a court of competent jurisdiction. 
 6. Governing Law. Any and all actions or controversies arising out of this
Agreement, including, without limitation, tort claims, shall be governed by and construed and enforced in accordance with the internal laws of New Jersey (without reference to principles of conflicts or choice of law that would cause the application
of the internal laws of any other jurisdiction). 
 7. Notices. All notices, requests, instructions or other documents to be given
hereunder shall be in writing or by written telecommunication, and shall be deemed to have been duly given if (i) delivered personally (effective upon delivery), (ii) mailed by certified mail, return receipt requested, postage prepaid
(effective five business days after dispatch), (iii) sent by a reputable, established courier service that guarantees next business day delivery (effective the next business day), or (iv) sent by telecopier followed within 24 hours by
confirmation by one of the foregoing methods (effective upon receipt of the telecopy in complete, readable form), addressed to the Company at the address set forth above and to the Employee at the address set forth in the Company’s records or
at such other address as such party may have supplied for the purpose pursuant to this Section 7. 
 8. Captions. The captions
of sections or subsections of this Agreement are for reference only and shall not affect the interpretation or construction of this Agreement. 

9. Severability. In the event that any provision of this Agreement shall, in whole or in part, be determined to be invalid,
unenforceable or void for any reason, such determination shall affect only the portion of such provision determined to be invalid and unenforceable or void and shall not affect in any way the remainder of such provision or any other provision of
this Agreement. 

  
 7 

 10. Binding Effect: Benefits: Assignment. This Agreement shall be binding upon the
parties hereto and their heirs, executors, administrators and other legal representatives and shall inure to the benefit of the parties hereto and the Company’s successors, and assigns. This Agreement may be assigned, without consent of the
Employee, by the Company to any corporation or other entity which succeeds to the business of the Company or which has purchased substantially all the stock or assets of the Company. The Employee may not assign the Employee’s rights or delegate
the Employee’s obligations under this Agreement and any such attempted assignment or delegation shall be void and of no effect. Nothing in this Agreement is intended to or shall confer any rights or remedies on any third party other than the
parties hereto and the Company’s successors and assigns. 
 11. Entire Agreement; Amendment; Waiver.

(a) This Agreement (including the Attachments) and the offer letter set forth the sole and entire agreement and understanding between the Company and the
Employee with respect to the specific matters contemplated and addressed hereby. No prior agreement or understanding, whether written or oral, shall be construed to change or affect the operation of this Agreement in accordance with its terms, and
any provision of any such prior agreement which conflicts with or contradicts any provision of this Agreement is hereby revoked and superseded. Any change or changes in Employee’s duties or compensation will not affect the validity or scope of
this Agreement. 
 (b) This Agreement may be amended only by a written instrument executed both by the Employee and by an authorized executive officer
(other than the Employee if the Employee is an executive officer) of the Company on behalf of the Company. 
 (c) No consent to or waiver of any
breach, default or violation in the performance of any obligation of the Employee hereunder, and no failure by the Company to complain of any such breach, default or violation, shall be effective unless it is in writing and executed by an executive
officer of the Company (other than the Employee if the Employee is an executive officer) on behalf of the Company. No such consent, waiver or failure to complain shall be deemed to be a consent to or waiver of any other breach, default or violation
of either the same or any other obligation of the Employee hereunder, whether occurring prior to or after such consent, waiver or failure to complain. 

12. At-Will Employment. The Employee acknowledges that his/her employment with the Company is “at-will.” The Employee understands that
nothing contained in this Agreement shall give the employee the right to continue in the employ of the Company. 
 [The remainder of this
page is intentionally left blank.] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the date written above as a sealed
instrument. 
  

			
	COMPANY:
	
	ROKA BIOSCIENCE, INC.
		
	By:	 	 
	Laurie A. Marsh
	Director, Human Resources

  

					
	EMPLOYEE:	 		 	
	   
	 		 	   

	Print Name	 		 	Signature

  
 9 

 Attachment 1 

California Labor Code Section 2870 

Employment Agreements; Assignment of Rights 

“2870. (a) Any provision in an employment agreement which provides that an employee shall assign, or
offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade
secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the
employer; or (2) Result from any work performed by the employee for the employer. 
 (b) To the extent a provision in an
employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is
unenforceable.” 

  
 10 

 Attachment 2 

Disclosure of Prior Inventions 

NAME:
 DATE: 

I hereby certify to Roka Bioscience Inc. (the “Company”) that, prior to the commencement of my employment with, or engagement to provide services
for, the Company (choose the applicable statement below and sign, where indicated): 
          I have no
Prior Inventions*
 Signature of
Employee:                                       
                                   

         I have Prior Inventions*, which are listed below 

Signature of
Employee:                                       
                                   

*”Prior Inventions” has the meaning set forth in the Agreement to which this Attachment 2 is annexed.

The following is a complete list of all Prior Inventions (Attach additional sheets as necessary). 

 

											
		 	Prior Invention	 		  	Identification Number	  		  	Brief Description
						
	1.	 	 	 		  	 	  		  	 
						
	2.	 	 	 		  	 	  		  	 
						
	3.	 	 	 		  	 	  		  	 

  
 11EX-10.11

 Exhibit 10.11 
 SERIES C PREFERRED STOCK 
 PURCHASE AGREEMENT

 This Series C Preferred Stock Purchase Agreement, dated as of April 29, 2011 (this
“Agreement”), is entered into by and among Roka Bioscience, Inc., a Delaware corporation (the “Company”), and the several purchasers named in Attachment 1 attached hereto (each a “Purchaser”
and collectively, the “Purchasers”). 
 WHEREAS, the Company desires to sell, and the Purchasers desire
to purchase, shares of its Series C Preferred Stock, $0.001 par value per share (“Series C Preferred Stock”); 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:

 1. AUTHORIZATION AND SALE OF SHARES. 
 1.1 Authorization. On or prior to the Closing Date (as defined below), the Company shall have (a) duly authorized the sale and issuance, pursuant to the terms of this Agreement, of up
to 15,094,340 shares of its Series C Preferred Stock (the “Shares”) and the issuance of such shares of Series A Common Stock of the Company, $0.001 par value per share (“Series A Common Stock”), to be issued upon
conversion of the Shares (the “Conversion Shares”), each having the rights, restrictions, privileges and preferences set forth in the Second Amended and Restated Certificate of Incorporation of the Company attached hereto as
Exhibit A (the “Charter”); and (b) adopted and filed the Charter with the Secretary of State of the State of Delaware. 
 1.2 Sale of Shares. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), the Company will sell and issue to each Purchaser, and each Purchaser, severally
and not jointly, will purchase from the Company, the number of shares of Series C Preferred Stock set forth opposite such Purchaser’s name on Attachment 1 at a purchase price of $1.325 per share, payable in cash by wire transfer to an
account designated by the Company. 
 2. THE CLOSING. 
 2.1 Closing. Subject to the satisfaction of all of the conditions set forth in Sections 5 and 6 hereof, the closing (“Closing”) shall be held at the offices of Lowenstein
Sandler PC, 65 Livingston Avenue, Roseland, New Jersey 07068, at 12:00 p.m. Eastern Daylight Time on             , 2011, or at such later time or such other place as the parties hereto
shall mutually agree. The date on which the Closing is actually held is referred to herein as the “Closing Date.” 
 2.2
Delivery. At the Closing, subject to the terms and conditions hereof, in addition to the deliveries required pursuant to Section 5 hereof, the Company will deliver to each Purchaser a certificate representing the number of Shares
purchased at such Closing by such Purchaser, against payment of the purchase price therefor. 

 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. Subject to and except as disclosed by the Company
in the schedules attached hereto specifically identifying the relevant subparagraph(s) hereof, the Company hereby represents and warrants to the Purchasers, as of the date hereof unless otherwise specified, as follows: 

3.1 Organization and Standing. The Company is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware and has full power and authority to own and operate, license or lease its properties, whether tangible or intangible, and conduct its business as currently conducted and as proposed to be conducted by it and to enter into and
perform this Agreement (including all schedules and exhibits hereto) and each of the other agreements required to be executed by the Company on or prior to the Closing pursuant to Section 5.1 hereof (the “Ancillary Agreements”)
and to carry out the transactions required to be executed by the Company contemplated by this Agreement and the Ancillary Agreements. The Company is duly qualified to do business as a foreign corporation and is in good standing in every jurisdiction
in which the failure to so qualify is reasonably likely to have a Material Adverse Effect. The Company has furnished to counsel to the Purchasers true and complete copies of the Charter and the Company’s By-Laws (the
“By-Laws”), each as amended to date and as presently in effect. 
 3.2 Authority for Agreement. The execution,
delivery and performance by the Company of this Agreement (including all schedules and exhibits hereto) and each of the Ancillary Agreements to which the Company is a party, and the consummation by the Company of the transactions contemplated hereby
and thereby, have been duly authorized by all necessary corporate action. This Agreement (including all schedules and exhibits hereto) and the Ancillary Agreements to which the Company is a party have been duly executed and delivered by the Company
and constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, receivership, moratorium or
other similar laws affecting the enforcement of creditors’ rights generally and (ii) the availability of equitable remedies may be limited by equitable principles of general applicability. The execution of, and performance of, the
transactions contemplated by this Agreement (including all schedules and exhibits) and the Ancillary Agreements and compliance with the respective provisions thereof by the Company will not, to the Company’s knowledge, violate any provision of
law and will not conflict with or result in any material breach of any of the terms, conditions or provisions of, or constitute a material default under, or require a consent or waiver under, (x)(i) the Charter or the By-Laws or (ii) any
material indenture, lease, agreement or other instrument to which the Company is a party or by which it or any of its properties (whether tangible or intangible) is bound, or (y) any decree, judgment, order, statute, rule or regulation
applicable to the Company. 
 3.3 Governmental Consents. Except for such qualifications or filings under applicable securities
laws as may be required in connection with the transactions contemplated by this Agreement or as provided in Schedule 3.3 hereto, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any governmental authority is required on the part of the Company in connection with the execution and delivery of this Agreement (including all schedules and exhibits hereto) and the Ancillary Agreements to which the Company is a
party, the offer, issuance, sale and delivery of the Shares (and the Conversion Shares), or the other transactions to be consummated at the Closing, as contemplated by this Agreement (including all schedules and exhibits hereto), except such filings
as shall have been made prior to and shall be effective on and as of the Closing. Based in part on the representations made by the Purchasers in Section 4 hereof, the offer, sale and issuance of the Shares to the Purchasers will be in
compliance with all applicable federal and state securities laws. 

  
 -2-

 3.4 Litigation. Except as provided in Schedule 3.4 hereto, there is no action, suit or
proceeding, or governmental inquiry or investigation, pending against the Company or, to the Company’s knowledge, threatened against the Company or threatened or pending against any of the Company’s directors or executive officers,
including, without limitation, any litigation which questions the validity of this Agreement (including all schedules and exhibits hereto) or the Ancillary Agreements or the right of the Company to enter into any of them, nor is there any litigation
pending against the Company or, to the Company’s knowledge, threatened against the Company or threatened or pending against any of the Company’s directors or executive officers by reason of activities of the Company or negotiations by the
Company or any of the directors or executive officers with possible investors in the Company. There is not any action, suit, proceeding or investigation pending or, to the Company’s knowledge, threatened against the Company involving the prior
employment of any of the Company’s employees or their obligations under any agreements with prior employers. Except as provided in Schedule 3.4 hereto, there is no action, suit, proceeding or investigation by the Company currently
pending or that the Company intends to initiate. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. 

3.5 Capitalization. Upon filing the Charter and prior to the issuance of the Shares hereunder, the Company has a total authorized
capitalization consisting of: (a) 90,839,952 shares of Common Stock, par value $0.001 par value per share (the “Common Stock”), of which (i) 78,710,428 shares have been designated Series A Common Stock, of which
(A) 4,571,428 shares are issued and outstanding; (B) 12,129,524 shares have been reserved for issuance upon conversion of the Company’s Series A Preferred Stock, $0.001 par value per share (“Series A Preferred
Stock”); (C) 37,200,000 shares have been reserved for issuance upon conversion of the Series B Preferred Stock, $0.001 par value per share (“Series B Preferred Stock”); (D) 15,094,340 shares have been reserved for
issuance upon conversion of the Series C Preferred Stock; (E) 2,480,000 shares have been reserved for issuance upon exercise of outstanding warrants; and (F) 7,235,136 shares will be reserved for issuance under the Company’s 2009
Equity Incentive Plan, as amended (the “Plan”), and (ii) 12,129,524 shares have been designated Series B Common Stock, $0.001 par value per share, all of which have been reserved for issuance upon conversion of Series A-1
Preferred Stock, $0.001 par value per share (“Series A-1 Preferred Stock”), and/or certain shares of Series A Common Stock in accordance with the Company’s Charter, as the case may be; and (b) 79,033,388 shares of
Preferred Stock, $0.001 par value per share (the “Preferred Stock”), of which (i) 12,129,524 shares have been designated as Series A Preferred Stock, of which 11,043,736 are issued and outstanding; (ii) 12,129,524 shares
have been designated Series A-1 Preferred Stock, of which 1,085,788 are issued and outstanding; (iii) 39,680,000 shares have been designated Series B Preferred Stock, 37,200,000 of which are issued and outstanding and 2,480,000 of which are
reserved for issuance upon exercise of outstanding warrants; and (iv) 15,094,340 shares have been designated Series C Preferred Stock, 15,094,340 of which will be issued and outstanding upon issuance pursuant to this Agreement. All of the
issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid and nonassessable, and were issued in accordance with the registration or qualification provisions of the Securities
Act of 1933, as amended (the “Securities Act”). Except as set forth in Schedule 3.5 

  
 -3-

 
or as otherwise provided in this Agreement, immediately prior to and after the Closing, (1) no subscription, warrant, option, convertible security or other right (contingent or otherwise) to
purchase or acquire any shares of capital stock of the Company is authorized or outstanding, (2) the Company has no obligation (contingent or otherwise) to issue any subscription, warrant, option, convertible security or other such right or to
issue or distribute to holders of any shares of its capital stock any evidences of indebtedness or assets of the Company, and (3) the Company has no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any shares of its
capital stock or any interest therein or to pay any dividend or make any other distribution in respect thereof. The issuance and sale of the Shares and all other outstanding shares of capital stock of the Company is in compliance with any and all
applicable rights of first refusal, preemptive rights or similar rights of any third party. The rights, preferences, privileges and restrictions of the Shares are as stated in the Charter. 
 3.6 Subsidiaries. The Company has no subsidiaries and does not own or control, directly or indirectly, any shares or units of capital securities of any other corporation or any interest in
any partnership, joint venture or other non-corporate business or charitable enterprise. 
 3.7 Stockholder List and Agreements.
Attached as Schedule 3.7 hereto is a true and complete list of the stockholders, option holders and warrant holders of the Company immediately prior to the Closing, showing the number of shares of Common Stock, Preferred Stock, options to
purchase shares of Common Stock and warrants exercisable for shares of Common Stock held by each. Except as provided in Schedule 3.7 hereto, there are no agreements, written or oral, between the Company and any holder of its capital stock
(including holders of derivative securities) or, to the Company’s knowledge, among any holders of its capital stock (including holders of derivative securities), relating to the acquisition (including, without limitation, rights of first
refusal, preemptive rights or similar rights), disposition, registration under the Securities Act, including the regulations promulgated thereunder, or voting of the capital stock (including derivative securities) of the Company. To the
Company’s knowledge, none of such Persons has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a direct business relationship, or any firm or corporation
that competes with the Company, except that employees, officers, or directors of the Company and members of their immediate families may own securities of publicly traded companies (not to exceed 2% of such companies’ capital stock) that may
compete with the Company. 
 3.8 Issuance of Shares. The issuance, sale and delivery of the Shares in accordance with this
Agreement, and the issuance and delivery of the shares of Series A Common Stock issuable upon conversion of the Shares, have been duly authorized by all necessary corporate action on the part of the Company, and all such shares have been duly
reserved for issuance. The Shares when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement, and the Conversion Shares, if and when issued upon such conversion, will be duly and validly issued,
fully paid and nonassessable. 
 3.9 Financial Statements. Set forth on Schedule 3.9 is the last regularly prepared
financial statements completed prior to such Closing (the “Financial Statements”, and the date of the balance sheet included in the Financial Statements, the “Balance Sheet Date”).

  
 -4-

 
The Financial Statements are complete and correct, are in accordance with the books and records of the Company and present fairly the financial condition, cash flow, changes in stockholder equity
and results of operations of the Company as at the dates and for the periods indicated, subject in the case of unaudited financial statements to normal year-end audit adjustments and the absence of footnotes. The Financial Statements have been
prepared in accordance with Generally Accepted Accounting Principles applied on a consistent basis throughout the periods indicated, except that the unaudited financial statements may not contain all footnotes required by Generally Accepted
Accounting Principles. 
 3.10 Absence of Changes. Since the Balance Sheet Date and except as provided in Schedule 3.10
there has not been: (a) any change in the assets, liabilities, financial condition or operations of the Company from that reflected in the Financial Statements, except changes in the ordinary course of business that have not had and cannot
reasonably be expected to have a Material Adverse Effect; (b) any change, except changes in the ordinary course of business that have not had and cannot reasonably be expected to have a Material Adverse Effect, in the contingent obligations of
the Company by way of guaranty, endorsement, indemnity, warranty or otherwise; (c) any damage, destruction or loss, whether or not covered by insurance, having or which could reasonably be expected to have a Material Adverse Effect;
(d) any waiver or compromise by the Company of a valuable right or of a material debt owed to it; (e) any loans made by the Company to the Company’s employees or directors other than travel advances made in the ordinary course of
business; (f) any extraordinary increases in the compensation of any of the Company’s employees or directors; (g) any declaration or payment of any dividend or other distribution of the assets of the Company; (h) any issuance or
sale by the Company (whether or not contingent) of any shares of its Common Stock, Preferred Stock or any other securities (including derivative securities); (i) any transaction or agreement consummated or entered into by the Company other than
in the ordinary course of business; (j) to the Company’s knowledge, any other event or condition of any character that has or is reasonably likely to have a Material Adverse Effect; (k) any sale, assignment or transfer of any patents,
trademarks, copyrights, trade secrets or other intangible assets (except for a license granted in the ordinary course of business); or (l) the entrance by the Company into any agreement or commitment or the arising of any obligation by the
Company to do any of the things described in this Section 3.10. 
 3.11 Taxes. The Company has filed or has obtained presently
effective extensions with respect to all federal, state, county, local and foreign tax returns which are required to be filed by it (including, without limitation, those due in respect of its properties, income, franchises, licenses, sales and
payrolls) and all taxes shown thereon to be due have been timely paid with exceptions not material to the Company. The Company has paid all taxes and other assessments due. Federal income tax returns of the Company have not been audited by the
Internal Revenue Service, and no controversy with respect to taxes of any type is pending or, to the Company’s knowledge, threatened. 

3.12 Property and Assets. 
 (a) The Company has good, clear, transferable and marketable title to all of its material properties and assets, whether tangible or intangible, and none of such properties or assets is subject to any
mortgage, pledge, lien, security interest, lease, license, charge or encumbrance, other than (i) those resulting from taxes which have not yet become delinquent, (ii) minor liens and encumbrances

  
 -5-

 
which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company, and (iii) those that have otherwise arisen in the ordinary
course of business. 
 (b) The Company has not granted rights to manufacture, produce, assemble, license, market or sell its
products to any Person and is not bound by any agreement that adversely affects the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell its products. 

(c) The Company hereby represents that it is not now and has never been a “United States real property holding corporation”, as
defined in Section 897(c)(2) of the Internal Revenue Code of 1986, as amended (the “Code”), and Treasury Regulation Section 1.897-2(b), and that the Company has filed with the Internal Revenue Service all statements, if
any, with its United States income tax returns, which are required under Treasury Regulation Section 1.897-2(h). 
 3.13 Intellectual
Property. 
 (a) Schedule 3.13(a) lists all patents, patent applications, trademarks, service marks,
trademark and service mark registrations and registration applications, trade names, trade name registrations, logos, trade dress, and copyright registrations that are directly or indirectly owned or controlled in whole or in part by the Company or
used in the business of the Company as now being conducted (collectively, “Intellectual Property”), including, in the case of any Intellectual Property not owned by the Company, the licenses or other agreements or arrangements
(other than for off-the-shelf software programs that have not been customized for its use) pursuant to which the Company has the right to use such Intellectual Property. Except as set forth in Schedule 3.13(a) and excluding
off-the-shelf software programs that have not been customized for its use, (i) the Company owns, or is licensed or authorized or otherwise has the right to use all Intellectual Property as it is being used in the business of the Company as now
being conducted without the payment of royalties or other consideration (including any obligations to issue equity securities to any third party); and (ii) no governmental registration of any of the Intellectual Property has lapsed, expired or
been cancelled, abandoned, opposed or the subject of a reexamination request. 
 (b) In any instance where the Company’s
rights to Intellectual Property arise under a license or similar agreement (other than for off-the-shelf software programs that have not been customized for its use), this is indicated in Schedule 3.13. Except for Intellectual Property
(i) indicated in Schedule 3.13(b) as owned by a third party and used by the Company under a license or similar agreement, or (ii) indicated in Schedule 3.13(b) as owned by the Company and licensed to a third
party, the Company has not granted to any other Person and, to the knowledge of the Company, no other Person has, an interest in or right or license to use any of the Intellectual Property. To the Company’s knowledge, none of the Intellectual
Property is being infringed by others, or is subject to any outstanding order, decree, judgment, or stipulation. No litigation (or other proceeding in or before any governmental agency or arbitral body) relating to or challenging the scope, validity
or enforceability of any of the Intellectual Property is pending, or to the Company’s knowledge, threatened, nor, to the Company’s knowledge, is there any basis for any such litigation or proceeding. The Company has kept secret and has not
disclosed, except pursuant to written confidentiality agreements, any trade secrets or confidential information 

  
 -6-

 
included in the Company’s Intellectual Property and maintains reasonable security measures for the preservation of the secrecy and proprietary nature of its trade secrets or other
confidential information included in the Company’s Intellectual Property including the use of written confidentiality agreements with any Person receiving the same. 
 (c) To the Company’s knowledge: (i) the Company has not infringed or made unlawful use of, and is not infringing or making unlawful use of, any intellectual property or other proprietary or
confidential information of any other Person; and (ii) the activities of the Company’s employees and contractors in connection with their employment or contractual relationship with the Company do not violate any agreements or arrangements
that any such employees or consultants have with any former employer or any other Person. No litigation (or other proceeding in or before any governmental agency or arbitrator body) charging the Company with infringement or unauthorized or unlawful
use of any patent, trademark, service mark, copyright or trade secret is pending, or to the Company’s knowledge, threatened. 
 (d) To the Company’s knowledge, no officer, director, employee, or consultant of the Company is obligated under or bound by any agreement or instrument, or any judgment, decree, or order of any court
or administrative agency, that conflicts or may conflict with his or her agreements and obligations to promote the interests of the Company. 

3.14 Insurance. The Company maintains insurance covering its properties and business adequate and customary for the type and scope of the
Company’s properties and business. A list of all of the insurance coverage maintained by the Company is set forth in Schedule 3.14 hereto. The Company is not in default with respect to payment of premiums on any such policy of
insurance and no claim is pending under any such policy. 
 3.15 Material Contracts and Obligations. Except as contemplated by
this Agreement or as listed in Schedule 3.15 hereto, the Company is not a party to any material agreement or commitment of any nature, including without limitation: (a) any agreement that requires future expenditures by the
Company in excess of $50,000 either individually or in the aggregate, (b) any employment or consulting agreement, employee benefit, bonus, pension, profit-sharing, stock option, stock purchase or similar plan or arrangement, (c) any
agreement with any stockholder, officer, director or, to the Company’s knowledge, Affiliate (as such term is defined below) of the Company or any of their respective immediate family members, including without limitation any agreement or other
arrangement providing for the furnishing of services by, rental of real or personal property from, or otherwise requiring payments to, any such Person (to the Company’s knowledge, none of such Persons has any direct or indirect ownership
interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation that competes with the Company, except that employees, officers, or directors of the Company
and members of their immediate families may own securities of publicly traded companies (not to exceed two percent (2%) of such companies’ capital stock) that may compete with the Company), (d) any agreement relating to the transfer
or license of any Intellectual Property, or (e) agreements restricting the development, manufacture or distribution of the Company’s products or services, including any distributor or sales representative agreements. As to each agreement
or commitment listed in Schedule 3.15: (i) the Company is not in material default thereunder, and, to the Company’s knowledge, no other party thereto is in material default thereunder; (ii) no event has occurred which is or, after the
giving of notice or passage of time or both, would constitute a material breach thereof by the Company or, to the Company’s 

  
 -7-

 
knowledge, by any other party thereto; (iii) the Company has not received written notice of an intention to cancel or terminate such agreement or commitment; and (iv) the consummation
of the transactions contemplated hereby will not constitute a material default thereunder or material breach thereof. The term “Affiliate” means any Person directly or indirectly controlling, controlled by or under common control
with another Person. 
 3.16 Absence of Undisclosed Liabilities. The Company has not (i) declared or paid any dividends or
authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $10,000 or, in the case of indebtedness
and/or liabilities individually less than $10,000, in excess of $100,000 in the aggregate (except for current liabilities incurred in the ordinary course of business), (iii) made any loans or advances to any Person, other than ordinary advances
for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory or license grants in the ordinary course of business. Except as listed in Schedule 3.16
hereto or as fully disclosed or reserved for in the Financial Statements, the Company does not, to its knowledge, have any material obligations or liabilities (whether accrued, absolute, contingent, liquidated, unliquidated or otherwise, whether due
or to become due) (“Liabilities”) required by generally accepted accounting principles to be reflected on a balance sheet except (i) liabilities and obligations incurred after the date of the Financial Statements and
(ii) future performance obligations under the agreements and commitments to which or by which the Company is bound as of the date hereof. 

3.17 Compliance. The Company has, to its knowledge, complied with all laws, regulations and orders applicable to its present business and
has all material permits and licenses required thereby, except for any violation of or default under any laws, regulations or orders which will not have a Material Adverse Effect. There is no term or provision of any mortgage, indenture, contract,
agreement or instrument to which the Company is a party or by which it is bound or, to the Company’s knowledge, of any provision of any state or federal judgment, decree, order, statute, rule or regulation applicable to or binding upon the
Company that has a Material Adverse Effect or, as far as the Company may now foresee, in the future is reasonably likely to have a Material Adverse Effect. 
 3.18 Employees. Set forth in Schedule 3.18 hereto is a list of the names of the executive officers and all other employees of the Company, together with the title or job
classification of each such individual. Except as set forth in Schedule 3.18 hereto, none of such Persons has an employment agreement or understanding, whether oral or written, with the Company that is not terminable on less than 90
days’ notice by the Company without cost or other liability to the Company. All Persons identified in Schedule 3.18 have executed and delivered nondisclosure and assignment of invention agreements in the form of Exhibit G
attached hereto, and all of such agreements are in full force and effect. The Company is not aware that any of its employees are in violation thereof. None of the Company’s employees is represented by any labor union, and there is no labor
strike or other labor trouble pending or, to the Company’s knowledge, threatened with respect to the Company (including, without limitation, any organizational drive). 
 3.19 ERISA. Except as set forth in Schedule 3.19 hereto, the Company does not have or otherwise contribute to or participate in any employee benefit plan subject to the
Employee Retirement Income Security Act of 1974, as amended. Schedule 3.19 hereto sets forth all of the employee benefit plans of the Company. 

  
 -8-

 3.20 Minute Books. The minute books of the Company accurately reflect all material information
relating to the meetings and other corporate actions of the Company’s stockholders and the Company’s Board of Directors (the “Board of Directors”) and any committees thereof. The stock ledger of the Company is complete and
reflects all issuances, transfers, repurchases and cancellations of shares of capital stock of the Company. 
 3.21 Disclosures.
The Company has provided each Purchaser with all the information that such Purchaser has requested for deciding whether to purchase the Series C Preferred Stock. The Company has provided the Purchasers with all material information that the Company
believes is reasonably necessary to enable such Purchasers to decide whether to purchase the Series C Preferred Stock, other than such information relating to matters which are not reasonably likely to have a Material Adverse Effect on the Company.
Neither this Agreement (including all schedules and exhibits hereto), nor the Ancillary Agreements (including all exhibits, annexes and schedules thereto), nor any report, certificate or instrument furnished to the Purchasers or its counsel in
connection with the transactions contemplated by this Agreement when read together, contains any untrue statement of a material fact or, to the Company’s knowledge, omits to state a material fact necessary in order to make the statements
contained herein or therein, in light of the circumstances under which they were made, not misleading. 
 3.22 Brokers. Except as
set forth in Schedule 3.22, the Company has not retained any finder or broker in connection with the transactions contemplated by this Agreement and agrees to indemnify and save the Purchasers harmless from and against any and all
claims, liabilities or obligations with respect to brokerage or finders’ fees or commissions in connection with the transactions contemplated by this Agreement asserted by any Person on the basis of any agreement, statement or representation
alleged to have been made by the Company. 
 3.23 Third Party Consents. Except as set forth in Schedule 3.23, to the
Company’s knowledge, no consent or approval is needed from any third party in order to effect the issuance and sale of the Shares (and the Common Stock issuable upon conversion of the Shares) or any of the other transactions contemplated by
this Agreement (including schedules and exhibits hereto) and the Ancillary Agreements. 
 4. REPRESENTATIONS AND WARRANTIES OF THE
PURCHASERS. Each of the Purchasers represents and warrants to the Company, on behalf of itself and not on behalf of the others, as follows: 

4.1 Accredited Investor. Such Purchaser is an “accredited investor” within the meaning of Rule 501(a) under the Securities Act,
and understands that the Company has relied upon its being an accredited investor in deciding to proceed with the transactions contemplated hereby, and in ascertaining the requirements of law applicable to the issuance and sale of the Shares. The
Purchaser’s financial condition is such that the Purchaser is able to bear all economic risks of investment in the Shares, including a complete loss of the Purchaser’s investments therein. The Purchaser acknowledges that the Company has
provided it with adequate access to financial and other information concerning the Company as requested and that it has had the opportunity to ask questions of and 

  
 -9-

 
receive answers from the Company concerning the transactions contemplated under this Agreement and the Ancillary Agreements and to obtain therefrom any additional information necessary to make an
informed decision regarding an investment in the Company. 
 4.2 Investment. The Purchaser is acquiring the Shares, and the shares
of Series A Common Stock into which the Shares may be converted, for its own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same;
and, except as contemplated by this Agreement and the Ancillary Agreements, the Purchaser has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. 

4.3 Authority. The Purchaser has full power and authority to enter into and to perform this Agreement and the Ancillary Agreements in
accordance with their respective terms. The Purchaser represents that it has not been organized, reorganized or recapitalized specifically for the purpose of investing in the Company. This Agreement and the Ancillary Agreements have been duly
executed and delivered by the Purchaser and constitute valid and binding obligations of each enforceable against it in accordance with their respective terms. The execution of and performance of the transactions contemplated by this Agreement and
the Ancillary Agreements and compliance with the respective provisions thereof by each of the Purchasers will not, to its knowledge, violate any provision of law and, if applicable, will not conflict with or result in any material breach of any of
the terms, conditions or provisions of or constitute a material default under, or require a consent or waiver under, its organizational documents (if any, and each as amended to date and as in effect as of the date hereof) or any indenture, lease,
agreement or other instrument to which the Purchaser is a party or by which it or any of its properties (whether tangible or intangible) is bound, or any decree, judgment, order, statute, rule or regulation applicable to the Purchaser. 

4.4 Unregistered Securities. The Purchaser acknowledges and agrees that the Shares, and any shares issuable upon conversion thereof, must
be held indefinitely until such time as they are subsequently registered under the Securities Act or an exemption from such registration is available. The Purchaser has been advised or is aware of the provisions of Rule 144 promulgated under the
Securities Act, which currently permits limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions, including, among other things: the availability of certain current public information about the
Company, the resale occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being through an unsolicited “broker’s transaction” or in transactions directly with a market maker (as
such term is defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and the number of shares being sold during any three-month period not exceeding specified limitations. 

4.5 Principal Place of Business. The address of the residence or the principal place of business, as applicable, the latter of which is the
office in which the Purchaser’s investment decision was made, is accurately set forth on Attachment 1. 
 4.6
Brokers. The Purchaser has not retained any finder or broker in connection with the transactions contemplated by this Agreement and the Purchaser separately agrees to indemnify and save the Company harmless from and against any and all
claims, liabilities or 

  
 -10-

 
obligations with respect to brokerage or finders’ fees or commissions in connection with the transactions contemplated by this Agreement asserted by any Person on the basis of any agreement,
statement or representation alleged to have been made by such Purchaser. 
 4.7 Foreign Investors. If the Purchaser is not a
United States Person (as defined by Section 7701(a)(30) of the Code), such Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the
Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any government or other
consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Shares. The Company’s offer and sale and Purchaser’s
subscription and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Purchaser’s jurisdiction. 
 4.8 Transfer Restrictions. Each Purchaser acknowledges and agrees that the Shares and, if issued, the Conversion Shares are subject to restrictions on transfer as set forth in the Investor
Rights Agreement. 
 5. CONDITIONS PRECEDENT OF THE PURCHASERS. Unless otherwise indicated below, the obligation of the Purchasers to
purchase Shares at the Closing is subject to the fulfillment, or the waiver by the Purchasers, of each of the following conditions (as applicable) on or before the Closing: 
 5.1 Ancillary Agreements. 
 (a) The Amended and Restated Investor
Rights Agreement in the form attached hereto as Exhibit B (the “Investor Rights Agreement”) shall have been executed and delivered by each of the parties thereto other than the Purchasers and shall be in full force and
effect. 
 (b) The Amended and Restated Voting Agreement in the form attached hereto as Exhibit C (the
“Voting Agreement”) shall have been executed and delivered by each of the parties thereto other than the Purchasers and shall be in full force and effect. 
 (c) The Amended and Restated Right of First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit D (the “Co-Sale Agreement”) shall have been executed and
delivered by each of the parties thereto other than the Purchasers and shall be in full force and effect. 
 5.2 Third Party
Consents. The Company shall have obtained any and all material consents, permits and waivers (including all authorizations, approvals or permits of any governmental authority or regulatory body of the United States of America or any state
thereof) necessary or appropriate for consummation of the transactions contemplated by this Agreement and the Ancillary Agreements, and the same shall be effective as of the date of the Closing, except for such as may be properly obtained subsequent
to the date of the Closing. 

  
 -11-

 5.3 Certificates and Documents. The Company shall have delivered to the Purchasers:
(a) certificates, as of the most recent practicable date, as to the corporate good standing of the Company issued by the Secretary of State of the State of Delaware; and (b) a Certificate of the Secretary or an Assistant Secretary of the
Company, dated as of the Closing Date, certifying: (i) that attached thereto is a true and complete copy of the Charter; (ii) that attached thereto is a true and complete copy of the By-Laws; (iii) that attached thereto is a true and
complete copy of the resolutions of the Board of Directors and the stockholders of the Company authorizing and approving all matters in connection with this Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby;
and (iv) to the incumbency and specimen signature of certain officers of the Company. 
 5.4 Representations and Warranties.
The representations and warranties of the Company contained in Section 3 shall be true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as
of the Closing Date; provided, however, that representations and warranties that speak as of a particular date shall remain so true and correct as of such date. 
 5.5 Performance. The Company shall have performed and complied with all agreements, obligations, covenants and conditions contained in this Agreement that are required to be performed or
complied with it at or before the Closing. 
 5.6 Compliance Certificate. At the Closing, the Chief Executive Officer of the
Company shall have delivered to the Purchasers a certificate certifying that the conditions specified in Sections 5.4 and 5.5 have been fulfilled and stating that there has been no Material Adverse Effect since the Balance Sheet Date other than as
disclosed in the Financial Statements or in this Agreement, including the schedules hereto. 
 5.7 Charter. The Charter shall have
been filed with the Secretary of State of Delaware and a certified copy of the Charter shall have been provided to the Purchasers. 
 5.8
Opinion of Counsel. The Purchasers shall have received an opinion from Lowenstein Sandler PC, counsel for the Company, dated as of the Closing Date, addressed to the Purchasers, satisfactory in form and substance to Purchasers, in the
form of Exhibit E attached hereto. 
 5.9 Management Rights Letter. A Management Rights Letter substantially in
the form attached hereto as Exhibit F-1 shall have been executed by the Company and delivered to the Purchasers associated with OrbiMed Advisors, LLC and a Management Rights Letter substantially in the form attached hereto as
Exhibit F-2 shall have been executed by the Company and delivered to New Enterprise Associates 13, LP. 
 6. CONDITIONS PRECEDENT
OF THE COMPANY. The obligation of the Company to issue Shares at the Closing is subject to the fulfillment, or the waiver by the Company, of each of the following conditions on or before the Closing: 

6.1 Ancillary Agreements. The Purchasers shall have executed and delivered the Voting Agreement, the Co-Sale Agreement and the Investor
Rights Agreement, and each such Ancillary Agreement shall be in full force and effect. 

  
 -12-

 6.2 Representations and Warranties. The representations and warranties of the Purchasers
contained in Section 4 shall be true and correct on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date. 

6.3 Performance. The Purchasers shall have performed and complied with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with at or before the Closing. 
 6.4 Third Party Consents. The Purchasers
shall have obtained any and all material consents, permits and waivers (including all authorizations, approvals or permits of any governmental authority or regulatory body of the United States of America or any state thereof) necessary or
appropriate for consummation of the transactions contemplated by this Agreement and the Ancillary Agreements, and the same shall be effective as of the date of the Closing, except for such as may be properly obtained subsequent to the date of the
Closing. 
 7. COVENANTS OF THE COMPANY 
 7.1 Nondisclosure Agreements. The Company shall require all persons now or hereafter employed by the Company or engaged by it as a consultant to enter into nondisclosure and assignment of
invention agreements if, and to the extent that, any have not previously been executed, substantially in the form of Exhibit G or such other form as may be approved from time to time by the Board of Directors. 

7.2 Reservation of Common Stock. The Company shall reserve and maintain a sufficient number of shares of Common Stock for issuance upon
conversion of all of the outstanding Shares, duly taking into account the reduction of shares available for issuance due to conversion of all of the Company’s convertible securities and exercise of all of the Company’s stock options as
well as any increase in the number of shares of Common Stock issuable upon conversion of all convertible securities in accordance with the terms of the Charter or upon exercise of all such options in accordance with the terms applicable thereto.

 7.3 Restrictive Agreements Prohibited. Neither the Company nor any of its subsidiaries, if any, shall become a party to any
agreement which, by its terms, restricts the Company’s ability to perform under or comply with the terms of this Agreement, the Ancillary Agreements to which the Company is a party or the Charter. 

7.4 Compliance with Laws. The Company shall comply, and cause each of its subsidiaries, if any, to comply, with all applicable laws, rules,
regulations and orders, the noncompliance with which is reasonably likely to have a Material Adverse Effect. 
 7.5 Amendment to Plan;
Restricted Stock Units. Immediately following the Closing, the Company shall (i) amend the Plan to increase the number of shares authorized for issuance under the Plan to 11,806,564 shares of Common Stock and (ii) issue to
Paul Thomas and Steven Sobieski Restricted Stock (as defined in the Plan) and/or Stock Grants (as defined in the Plan) pursuant to the terms of each of Paul Thomas’ and Steven Sobieski’s Restricted Stock Award Agreements with the Company.

  
 -13-

 7.6 FIRPTA. The Company shall provide prompt notice to the Purchasers following any
“determination date” (as defined in Treasury Regulation Section 1.897-2(c)(1)) on which the Company becomes a United States real property holding corporation. In addition, upon a written request by a Purchaser, the Company shall
provide such Purchaser with a written statement informing such Purchaser whether such Purchaser’s interest in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements of
Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2)
or any successor regulation, that such statement has been made. The Company’s written statement to such Purchaser shall be delivered to such Purchaser within ten (10) days of such Purchaser’s written request therefor. The
Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be regularly traded on an established securities market or the fact that there is no preferred stock
then outstanding. 
 8. MISCELLANEOUS. 
 8.1 Successors and Assigns. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by the Purchaser to any Person to which Shares are transferred by the
Purchaser, and such transferee shall be deemed to be the “Purchaser” for purposes of this Agreement; provided that the transferee provides written notice of such assignment to the Company and agrees in writing to be bound by and comply
with all provisions of this Agreement. 
 8.2 Survival of Representations and Warranties. All covenants, representations and
warranties contained herein shall survive the execution and delivery of this Agreement and the closing of the transactions contemplated hereby and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of
the Purchasers or the Company. 
 8.3 Indemnification.  

(a) The Company agrees to indemnify and hold harmless each Purchaser and its respective directors, officers, trustees, members, managers,
employees and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or
defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person (as defined below) may become subject as a result of any breach of representation,
warranty, covenant or agreement made by or to be performed on the part of the Company under this Agreement and the Ancillary Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person. 

(b) Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with
respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any Person entitled to indemnification
hereunder shall have the right to 

  
 -14-

 
employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (a) the indemnifying party
has agreed to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such Person or (c) in the reasonable judgment of any such Person,
based upon written advice of its counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party in writing that such Person elects to
employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and provided, further, that the failure of any indemnified
party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such
claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified
parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to
such indemnified party of a release from all liability in respect of such claim or litigation. 
 8.4 Expenses. The Company shall
pay from the proceeds of the sale of the Shares the reasonable due diligence and legal expenses of the Purchasers in connection with the transactions contemplated hereby. 
 8.5 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified,
(ii) when sent by confirmed electronic mail, telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (iii) five days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. 

If such notice is addressed to the Company, at 20 Independence Boulevard, 4th Floor, Warren, New Jersey 07059, Attention: Chief Executive
Officer, or at such other address or addresses as may have been furnished by ten days advance written notice in writing by the Company to such Purchaser. 
 If such notice is addressed to any Purchaser, at the address set forth in Attachment 1, or at such other address or addresses as may have been furnished by ten (10) days advance written
notice to the Company in writing by such Purchaser. 
 8.6 Entire Agreement. This Agreement and the Ancillary Agreements
(including all exhibits, schedules and annexes to each) and the Charter embody the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior agreements and understandings relating
to such subject matter. 

  
 -15-

 8.7 Amendments. Except as otherwise expressly set forth in this Agreement, any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company, the holders of at least
70% of the Shares purchased pursuant to this Agreement (treated as if converted and including any Conversion Shares into which the then outstanding Shares have been converted that have not been sold to the public) and the consent of the Preferred A
Stockholder Director (as defined in the Voting Agreement). Any amendment or waiver effected in accordance with this Section 8.7 shall be binding upon the Company, each Purchaser and each future holder of any Shares (including the Conversion
Shares). 
 8.8 Counterparts. This Agreement, and any amendment hereto, may be executed in one or more counterparts, each of which
shall be deemed to be an original, but all of which shall be one and the same document. 
 8.9 Section Headings; Schedules. The
section headings are for the convenience of the parties only and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. Any matter disclosed as to any section of this Agreement in the schedules hereto shall be
deemed to be disclosed as to all sections of the Agreement. 
 8.10 Severability. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 
 8.11 Governing
Law. This Agreement shall be governed by and construed in accordance with the internal, substantive laws of the State of Delaware excluding any choice of laws rule or principle that would result in the application of the substantive laws of
any other jurisdiction. The parties hereto agree that any action brought under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and
does hereby submit to the jurisdiction and venue of, any state or federal court located in the State of New Jersey. 
 8.12 No Implied
Rights or Remedies. Except as otherwise expressly provided herein, nothing herein expressed or implied is intended or shall be construed to confer upon or to give any Person, except the Purchasers and the Company, and their respective
successors and assigns permitted under this Agreement, any rights or remedies under or by reason of this Agreement. 
 8.13
Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their joint and mutual intent, and no rule of strict construction will be applied against any party. 

8.14 Singular, Plural, Etc. Words in the singular include the plural, and words in the plural include the singular, in each case as the
context may require. Where a provision is qualified with respect to knowledge of the Company, such knowledge shall be imputed if any individual Company officer actually possesses such knowledge. “Days” and any other measure of time
shall be construed to include weekends and holidays unless otherwise specified. “Person” means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust,
unincorporated organization or government (including any agency or 

  
 -16-

 
political subdivision thereof). In addition, the word “or” shall not be construed as requiring exclusivity. Whenever the context requires, the neuter gender shall include the masculine
and feminine genders. 
 8.15 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any
holder of any of the Shares, upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of such holder nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or
approval of any kind or character on the part of any holder of any breach or default under this Agreement, or any waiver on the part of any holder of any provisions or conditions of this Agreement, must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any holder, shall be cumulative and not alternative. 
 8.16 California Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF
CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH
CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE. 

8.17 Specific Performance. The parties hereto agree that: (a) in the event of any breach or threatened breach by any party of any
covenant, obligation, or other provision of this Agreement applicable to such party, the other party shall be entitled (in addition to any other remedy that may be available) to (i) a decree or order of specific performance or mandamus to
enforce the observance and performance of such covenant, obligation or other provision, and (ii) an injunction restraining such breach or threatened breach; and (b) neither such other party shall be required to provide any bond or other
security in connection with any such decree, order or injunction or in connection with any related action or proceeding. 
 8.18 Defined
Terms. As used herein, the following terms not otherwise defined have the following meanings: 
 “Material
Adverse Effect” means a material adverse effect on the business, assets, operations or condition, financial or otherwise, of the Company; provided however, in no event shall any of the following, either individually or in
combination, constitute a Material Adverse Effect: (a) changes in general business or economic conditions in the Company’s industry, (b) any circumstance, change, or effect solely resulting from or arising out of, directly or
indirectly, the fact that Company or any Purchaser (rather than another party) is a party to the transactions contemplated by this Agreement; or (c) any failure by Company to meet internal projections of forecasts or predictions for any period.

  
 -17-

 8.19 Other Defined Terms. Each of the following terms shall have the meanings ascribed to such
terms in the section set forth opposite such term: 
  

									
	 Defined Term
	  	 Section
	  	  	  	 Defined Term
	  	 Section

					
	Affiliate	  	3.15	  		  	Intellectual Property	  	3.13
					
	Agreement	  	Preamble	  		  	Investor Rights Agreement	  	5.1(a)
					
	Ancillary Agreements	  	3.1	  		  	Liabilities	  	3.16
					
	Balance Sheet Date	  	3.9	  		  	Losses	  	8.3(a)
					
	Board of Directors	  	3.20	  		  	Material Adverse Effect	  	8.18
					
	By-Laws	  	3.1	  		  	Person	  	8.14
					
	Charter	  	1.1	  		  	Preferred Stock	  	3.5
					
	Closing	  	2.1	  		  	Purchaser(s)	  	Preamble
					
	Closing Date	  	2.1	  		  	Securities Act	  	3.5
					
	[Intentionally Omitted]	  		  		  	Series A Common Stock	  	1.1
					
	Common Stock	  	3.5	  		  	Series A Preferred Stock	  	3.5
					
	Company	  	Preamble	  		  	Series A-1 Preferred Stock	  	3.5
					
	Conversion Shares	  	1.1	  		  	Series B Preferred Stock	  	3.5
					
	Co-Sale Agreement	  	5.1(c)	  		  	Series C Preferred Stock	  	Recitals
					
	Days	  	8.14	  		  	Shares	  	1.1
					
	Exchange Act	  	4.4	  		  	Voting Agreement	  	5.1(b)
					
	Financial Statements	  	3.9	  		  		  	

 [Remainder of page intentionally left blank.] 

  
 -18-

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the parties hereto have
caused this Series C Preferred Stock Purchase Agreement to be duly executed and delivered as an agreement under seal as of the date and year first above written. 
  

			
	ROKA BIOSCIENCE, INC.
		
	By:	 	 /s/ Paul Thomas

	Name:	 	Paul Thomas
	Title:	 	CEO
	
	ORBIMED PRIVATE INVESTMENTS III, LP
		
	BY:	 	ORBIMED CAPITAL GP III, LLC,
		 	ITS GENERAL PARTNER
		
	By:	 	 /s/ Jonathan Silverstein

	Name:	 	Jonathan Silverstein
	Title:	 	Member
	
	ORBIMED ASSOCIATES III, LP
		
	BY:	 	ORBIMED ADVISORS, LLC,
		 	ITS GENERAL PARTNER
		
	By:	 	 /s/ Jonathan Silverstein

	Name:	 	Jonathan Silverstein
	Title:	 	Member

 Signature Page to Stock Purchase Agreement 

  
 -19-

			
	NEW ENTERPRISE ASSOCIATES 13, LIMITED PARTNERSHIP
		
	BY:	 	NEA PARTNERS 13, LIMITED PARTNERSHIP,
		 	ITS GENERAL PARTNER
		
	BY:	 	NEA 13 GP, LTD,
		 	ITS GENERAL PARTNER
		
	By:	 	 /s/ Louis Citron

	Name:	 	Louis Citron
	Title:	 	Chief Legal Officer
	
	TPG BIOTECHNOLOGY PARTNERS III, L.P.
		
	BY:	 	TPG BIOTECHNOLOGY GENPAR III, L.P.,
		 	ITS GENERAL PARTNER
		
	BY:	 	TPG BIOTECHNOLOGY GENPAR III ADVISORS, LLC,
		 	ITS GENERAL PARTNER
		
	By:	 	 /s/ Ronald Cami

	Name:	 	Ronald Cami
	Title:	 	Vice President
	
	GEN-PROBE INCORPORATED
		
	By:	 	 /s/ Carl W. Hull

	Name:	 	Carl W. Hull
	Title:	 	President and CEO

 Signature Page to Stock Purchase Agreement 

  
 -20-

 ATTACHMENT 1 

 

									
	 Purchaser
	  	Aggregate Purchase Price	 	  	Shares Purchased	 
			
	 OrbiMed Private Investments III, LP
	  				  			
	  
 Address:

767 Third Avenue, 30th Floor

New York, NY 10017

Attn: Chief Financial Officer
	  				  			
	 Mail Certificates to:

Merrill Lynch, Venture Services

600 California Street, 8th Floor

San Francisco, CA 94108

Attn: Thomas Hutson-Wiley
	  	$	5,289,669.20	  	  	 	3,992,203	  
			
	 OrbiMed Associates III, LP
	  				  			
	  
 Address:

767 Third Avenue, 30th Floor

New York, NY 10017

Attn: Chief Financial Officer
	  				  			
	 Mail Certificates to:

Merrill Lynch Venture Services

600 California Street, 8th Floor

San Francisco, CA 94108

Attn: Thomas Hutson-Wiley
	  	$	50,377.80	  	  	 	38,021	  
			
	 New Enterprise Associates 13, Limited Partnership
	  				  			
	  
 Address:

1119 St. Paul Street

Baltimore, MD 21202

Attn:
[                    ]
	  	$	5,340,047.00	  	  	 	4,030,224	  
			
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.
	  				  			
			
	 Address:

345 California St.

Suite 3300
 San Francisco, CA 94104
 Attn:
[                    ]
	  	$	5,340,047.00	  	  	 	4,030,224	  
			
	 GEN-PROBE INCORPORATED
	  				  			
	  
 Address:

10210 Genetic Center Drive

San Diego, CA 92121-4362

Attn: General Counsel
	  	$	3,979,860.00	  	  	 	3,003,668	  
		  	  
	  
	 	  	  
	  
	 
			
	 TOTAL:
	  	$	20,000,001.00	  	  	 	15,094,340	  
		  	  
	  
	 	  	  
	  
	 

  
 -21-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]